The aprotinin saga and the risks of conducting meta-analyses on small randomised controlled trials – a critique of a Cochrane review

BACKGROUND: Aprotinin for reducing blood loss during coronary artery bypass surgery was withdrawn from the market after early termination of a large randomised controlled trial (RCT) showing excess mortality for patients receiving aprotinin compared to lysine analogues. Several meta-analyses of smal...

Descripción completa

Detalles Bibliográficos
Autor principal: Rosén, Måns
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2657782/
https://www.ncbi.nlm.nih.gov/pubmed/19228407
http://dx.doi.org/10.1186/1472-6963-9-34

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2657782/
https://www.ncbi.nlm.nih.gov/pubmed/19228407
http://dx.doi.org/10.1186/1472-6963-9-34

Ejemplares similares